Celgene, Novartis Settle With Barr Over Generic Ritalin

Law360, New York (April 26, 2010, 12:57 PM EDT) -- Celgene Corp. and Novartis AG have reached a settlement with Barr Laboratories Inc. over the generic-drug maker’s attempt to market its own version of blockbuster drug Ritalin, a treatment for attention deficit hyperactivity disorder.

Judge Freda L. Wolfson of the U.S. District Court for the District of New Jersey dismissed the suit Wednesday, after U.S. regulators approved a settlement between the plaintiffs and Barr, a subsidiary of Teva Pharmaceutical Industries Ltd.

The claims and counterclaims were dismissed without prejudice, and each side agreed to pay its...
To view the full article, register now.